Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer

This article was originally published here

IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable the development and accelerate the review of

The post Infinity gets FDA fast track status for IPI-549, Opdivo combo in urothelial cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply